Skip to main content
. 2020 Oct 15;54:235–241. doi: 10.1016/j.breast.2020.10.002

Fig. 2.

Fig. 2

Survival analysis in the whole population. (A) The estimated 5-year DFS rate was 87.4% for HER2-neg patients and 94.2% for HER2-pos patients treated with trastuzumab. HER2-pos-T was associated with significantly better DFS both in univariate analysis (Log-rank P = 0.014) and multivariate analysis (HR 0.38, 95% CI: 0.22–0.67, Log-rank P = 0.001). (B) The estimated 5-year OS rate was 95.7% in the HER2-neg group and 97.2% in the HER2-pos-T group (Log-rank P = 0.183). HER2-pos-T was associated with significantly better OS (HR 0.40, 95% CI: 0.17–0.95, Log-rank P = 0.037) after adjusting menstrual status, histological type, tumor size, ALN status, histological grade, ER, and PR. (C) Estimated and smoothed annual incidence of DFS events in the HER2-neg group and HER2-pos-T group ∗. (D) Estimated and smoothed annual incidence of OS events in the HER2-neg group and HER2-pos-T group ∗. ∗ In C/D panels, dots and triangles represent estimated annual incidence of DFS/OS events in the HER2-neg group and HER2-pos-T group, respectively.